Clinical DevelopmentThe next-generation AX-0810 has shown a 5.5-fold increase in potency over earlier NTCP EON iterations, along with improved stability in vitro and no evidence of hepatotoxicity or immunostimulatory effects, which indicates a favorable pharmacokinetic, pharmacodynamic, and safety profile.
Financial PositionPRQR ended with $156M in cash, which management estimates is sufficient runway into mid-2027.
Partnerships And CollaborationsProQR continues to execute on its partnership with Lilly, which includes potential data updates and milestone income.